Market Pulse Archives

Aug. 21, 2019, 7:42 a.m. EDT

Cerecor stock soars 17% premarket after FDA grants fast-track designation to treatment for rare disorder

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Cerecor Inc. (CERC)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Ciara Linnane

Shares of Cerecor Inc. /zigman2/quotes/201368871/composite CERC -4.80% rallied 17.5% in premarket trade Wednesday, after the biotech said the U.S. Food and Drug Administration has awarded it an expedited review process for a treatment for Mannose-Phosphate Isomerase Deficiency, or MPI-CDG, a rare metabolic disorder. The FDA has granted Rockville, Md.-based Cerecor Fast Trace Designation for its CERC-802 treatment, an oral formulation of D-mannose. CERC-802 is an ultra-pure formulation of D-mannose, a naturally occurring monosaccharide that is found in animals, microorganisms, and plants, including edible fruits and herbs. "CDG patients are born with a genetic defect that hinders their ability to utilize certain monosaccharides in the production of glycoproteins," the company explained. Shares have gained 19% in 2019, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.07% has gained 16%.

US : U.S.: Nasdaq
$ 3.57
-0.18 -4.80%
Volume: 145,694
Sept. 13, 2019 4:00p
P/E Ratio
Dividend Yield
Market Cap
$157.46 million
Rev. per Employee
-2.18 -0.07%
Volume: 1.89B
Sept. 13, 2019 4:56p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.